CSIMarket
 
Inmune Bio Inc   (INMB)
Other Ticker:  
 
 
Price: $11.0600 $-0.38 -3.322%
Day's High: $11.83 Week Perf: -5.63 %
Day's Low: $ 11.00 30 Day Perf: -21 %
Volume (M): 63 52 Wk High: $ 14.74
Volume (M$): $ 698 52 Wk Avg: $8.99
Open: $11.26 52 Wk Low: $5.87



 Market Capitalization (Millions $) 199
 Shares Outstanding (Millions) 18
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0

Inmune Bio Inc
Inmune Bio Inc. is a biotechnology company that focuses on developing novel immunotherapies to treat various types of diseases, particularly cancer and neurodegenerative disorders. The company utilizes its expertise in the field of immunology to develop innovative therapies that harness the power of the immune system. These therapies aim to stimulate the body's natural defense mechanisms to fight off diseases more effectively.

The company's approach involves the development of immunotherapies that target specific proteins or pathways involved in disease progression. Inmune Bio conducts extensive research and preclinical studies to identify potential targets and develop candidate drugs. They use a combination of cutting-edge technologies and biological platforms to design and optimize these therapies.

One of the key focuses of Inmune Bio is developing immunotherapies that target the tumor microenvironment. Their therapies aim to modulate the immune response in a way that enhances the body's ability to recognize and eliminate cancer cells. By manipulating the immune system, the company's therapies seek to improve patient outcomes and potentially reduce the need for traditional treatments such as chemotherapy or radiation.

In addition to cancer treatments, Inmune Bio is also involved in developing therapies for neurodegenerative disorders such as Alzheimer's disease. Their approach involves targeting specific proteins implicated in the progression of these disorders, with the goal of slowing down or halting disease progression.

Overall, Inmune Bio Inc. is dedicated to advancing the field of immunotherapy by developing innovative and effective treatments for cancer and neurodegenerative disorders. Through their research and development efforts, they aim to improve patient outcomes and provide new options for those suffering from these diseases.


   Company Address: 225 NE Mizner Blvd Boca Raton 33432 FL
   Company Phone Number: 964-3720   Stock Exchange / Ticker: NASDAQ INMB
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Inmune Bio Inc

Inmune Bio Inc Plummets with A Whopping -56% Revenue Drop in Q3 2023


Publication: The
Date: February 25, 2024
Inmune Bio Inc, a Biotechnology & Pharmaceuticals company, reported disappointing results for its most recent fiscal period. The company's revenue declined by a staggering -56.122% to $0.04 million, and the shortfall per share increased to $-0.48 compared to the same reporting period last year.
These grim figures stand in contrast to the rest of the Biotechnology & Pharmaceuticals sector, which saw a rise in revenue during the third quarter of 2023, albeit by a more modest -6.522% from $0.05 million. This highlights the challenges faced by Inmune Bio Inc and raises concerns about the future stability of the company.

Inmune Bio Inc

Inmune Bio Inc. Defies Biotech Trends with 187.5% Revenue Surge Despite Unexpected $-0.36 Per Share Shortfall in Q2 2023

During the past week, Inmune Bio Inc (INMB) stock experienced a decline of -6.28%. This has affected the year-to-date performance of the stock, which now stands at a positive 24.59%. Currently trading on the NASDAQ, INMB stock is 4.8% above its 52-week average. This recent performance has raised questions among investors and analysts alike.
However, the surprising aspect of INMB's behavior lies in its financial results. The biotechnology and pharmaceuticals company reported a remarkable revenue improvement of 187.5% year-on-year, reaching $0.05 million in the most recent fiscal period. Despite this positive revenue growth, INMB incurred a loss of $-0.36 per share.
INMB's revenue gain while the remainder of the biotechnology and pharmaceuticals sector experienced a -16.06% decline in business has left many puzzled. This divergence from industry trends has captured the attention of market participants.

Inmune Bio Inc

Inmune Bio Inc Faces Significant Challenges: Q1 2023 Earnings Recap Reveals Major Downturn

Inmune Bio Inc is a company that specializes in developing products and therapies for the treatment of various diseases related to the immune system. It focuses on developing immunotherapies for cancers and autoimmune disorders. The company has been facing a challenging period, as indicated by its financial results for the first quarter of 2023.
During the first quarter of 2023, Inmune Bio Inc reported a net deficit of $-6.536 million, which was marginally lower than the deficit of $-6.903 million it had reported in the same quarter a year before. However, the company's revenue went down sharply by 76.687% to $0.04 million from $0.16 million in the similar quarter a year before, and sequentially Revenue Tumbled by -60.825% from $0.10 million. As a result, the company's loss per share for the first quarter of 2023 was $-0.36, which was lower than the loss of $-0.39 per share that it had reported for the same quarter a year before. However, the company's deficit grew from $-0.31 per share from the prior quarter.






 

Inmune Bio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com